New immune combo targets hard-to-treat nose and throat cancer
NCT ID NCT07101744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus a targeted antibody (nimotuzumab) in people with advanced nasopharyngeal cancer that got worse after standard first treatment. About 41 adults aged 18-70 will receive the therapy to see if it shrinks tumors and how safe it is. The goal is to find a better option for this tough-to-treat cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIRST-LINE TREATMENT FAILURE NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could avoiding Pre-Radiation tooth removal protect jaw health?
- Can a blood test and MRI tailor cancer therapy to each patient?
- Can an immunotherapy boost standard treatment for a Head-and-Neck cancer?
- Can a Two-Pronged radiation strategy boost immunotherapy against advanced nasopharyngeal cancer?
- Can tumor genetics predict survival in nasopharyngeal cancer?
- Dual-Action antibody may boost chemoradiotherapy against High-Risk nasopharyngeal cancer